Back to search

Article

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary

2023-03-17

Abstract excerpt

Patients with cancer of unknown primary (CUP) carry the burden of an aggressive disease and reduced access to therapies. Experimental models are pivotal for CUP biology investigation and drug testing. We derived two CUP cell lines (CUP#55 and #96), and corresponding patient-derived xenografts (PDXs), from ascites tumor cells. CUP cell lines and PDXs underwent histological, immune-phenotypical, molecular, and genom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ac70ab7b-ed5e-5be7-a4a3-543faa642462
DOI
10.1101/2023.03.12.23287041
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primaryDOI 10.1101/2023.03.12.23287041
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.Semantic proximity
Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.Semantic proximity
Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Semantic proximity
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Semantic proximity
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity
Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.Semantic proximity
Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.Semantic proximity
Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.Semantic proximity
Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?Semantic proximity
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity
Stem-like cells from Cancer of Unknown Primary are endowed with distinctive hypermetastatic properties and unveil liability to MEK inhibitionSemantic proximity
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibitionSemantic proximity
Select a neighboring publication to make it the new centre.